CB2 exerts pro-tumor effects by suppressing cytotoxicity of CD8+ T cells and NK cells. Simultaneous antagonism of CB2 enhances anti-tumor effects of anti-PD-1 therapy. This evidence concerns the gene CNR2 and neoplasm.